While most people can manage their cholesterol through a healthy lifestyle and statins, some patients—especially those with genetic disorders or very high cardiovascular risk—require more advanced treatments. PCSK9 inhibitors are one such breakthrough.
Understanding Cholesterol
Cholesterol is a fatty substance produced by the liver and also obtained from food. While it plays vital roles in hormone production and cell structure, excess low-density lipoprotein (LDL) cholesterol—commonly referred to as “bad cholesterol”—can lead to atherosclerosis, where arteries become clogged with fatty deposits.
Recommended Cholesterol Levels (MOH Singapore Guidelines):
- LDL cholesterol:
- < 2.6 mmol/L for moderate cardiovascular risk
- < 1.8 mmol/L for high/very high risk individuals
- < 2.6 mmol/L for moderate cardiovascular risk
Cardiovascular Risk Factors Include:
- Hypertension
- Diabetes
- Smoking
- Family history of early heart disease
- Personal history of heart attack or stroke
First-Line Treatment: Lifestyle + Statins
In Singapore, the initial approach to managing high cholesterol includes:
🥗 Lifestyle Measures:
- Adopting a low-fat, high-fibre diet
- Regular physical activity (150 minutes/week)
- Smoking cessation
- Weight management
💊 Statins:
Statins are widely prescribed under schemes like CHAS, MediSave, or MediShield Life. They work by blocking cholesterol production in the liver and are effective in most patients.
However, some people experience side effects like muscle pain or liver enzyme abnormalities—or do not achieve target LDL levels despite maximum tolerated doses.
PCSK9 Inhibitors: A Game-Changer in Cholesterol Therapy
PCSK9 inhibitors are injectable biologic medications that reduce LDL cholesterol by enhancing the liver’s ability to clear it from the bloodstream. They target a protein called proprotein convertase subtilisin/kexin type 9 (PCSK9) which, when inhibited, increases the number of LDL receptors available to remove cholesterol.
Available in Singapore:
- Evolocumab (Repatha®)
- Alirocumab (Praluent®)
These drugs are typically administered every 2–4 weeks via subcutaneous injection.
*Repatha is currently in the Healthier SG Medication List, HSG patients may receive additional government subsidies for this medication.
Who Should Consider PCSK9 Inhibitors?
Your doctor may recommend PCSK9 inhibitors if you:
- Have familial hypercholesterolaemia (FH), a genetic condition with very high LDL from a young age
- Have had a heart attack, stroke, or other cardiovascular event
- Are intolerant to statins
- Still have elevated LDL despite maximally tolerated statin therapy
In a Singapore-based study, over 75% of patients with high cardiovascular risk did not achieve LDL targets with statins alone. (Toh et al., 2020, Singapore Medical Journal)
Clinical Evidence: How Effective Are PCSK9 Inhibitors?
Several landmark studies have demonstrated the power of PCSK9 inhibitors:
- FOURIER Trial (Sabatine et al., 2017, New England Journal of Medicine):
- Evolocumab reduced LDL by 59% and lowered the risk of major cardiovascular events by 15%.
- Evolocumab reduced LDL by 59% and lowered the risk of major cardiovascular events by 15%.
- ODYSSEY OUTCOMES Trial (Schwartz et al., 2018, NEJM):
- Alirocumab reduced cardiovascular events in patients with recent acute coronary syndrome.
- Alirocumab reduced cardiovascular events in patients with recent acute coronary syndrome.
These drugs have shown benefit even in patients already on high-dose statins.
Safety and Side Effects
PCSK9 inhibitors are generally well-tolerated. Reported side effects include:
- Mild injection site reactions
- Flu-like symptoms
- Nasal congestion or sore throat
Unlike statins, they do not cause muscle toxicity or liver enzyme elevation.
Cost and Subsidies in Singapore
PCSK9 inhibitors are biologic therapies and are currently not subsidised under standard government schemes such as CHAS or MediShield Life. However, financial assistance may be available through:
- Medication Assistance Fund (MAF)
- Means testing via public hospitals
- Private insurance plans covering high-risk individuals
Speak to your doctor to understand if you qualify for subsidy or support.
Take Charge of Your Heart Health
Effective cholesterol control is a key step in reducing your risk of heart attack, stroke, and premature death. For many Singaporeans, statins and lifestyle changes are sufficient. But if you’re not hitting your LDL targets, PCSK9 inhibitors may offer life-saving benefits.
🩺 Book an Appointment
Our clinic provides personalised cardiovascular risk assessments and advanced lipid management.
Contact us today to find out if PCSK9 inhibitors are suitable for you.
References
- Toh, W. Y., et al. (2020). Assessment of LDL-C Goal Achievement in High-Risk Patients in Singapore. Singapore Medical Journal. https://doi.org/10.11622/smedj.2020123
- Sabatine, M. S., et al. (2017). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 376:1713-1722.
- Schwartz, G. G., et al. (2018). Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med, 379:2097-2107.
- Ministry of Health Singapore. (2022). Chronic Disease Management Programme: Lipid Disorders. https://www.moh.gov.sg
